Structural and Functional Imaging and Cognitive Functions in Ovarian Cancer
NCT01591772 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 36
Last updated 2022-06-01
Summary
The purpose of this study is to learn about possible changes in brain anatomy and function, and in thinking abilities, such as memory skills, in patients with ovarian cancer who receive treatment with chemotherapy. Cancer patients treated with chemotherapy may experience changes in thinking abilities, and these may interfere with quality of life. Most of the research to date has involved patients with breast cancer, and there are no studies in women with ovarian cancer looking at at treatment-related changes in brain anatomy and function.
Conditions
- Fallopian Tube Cancer
- Ovarian Cancer
- Peritoneal Cancer
Interventions
- OTHER
-
Neuroimaging & Neuropsychological Evaluation
Will undergo structural and functional MRI scans on a Siemens 3T Magnetom Tim Trio research scanner located at the Citigroup Biomedical Imaging Center at Weill Cornell Medical Center (WCMC), which is adjacent to the MSKCC campus. Patients do not undergo routine clinical brain MRIs as part of their assessment and treatment, and the brain MRI scans to be performed in this study are for research purposes only. The MRI scan takes approximately 60 minutes to complete, and about 15 minutes will be required for instructions prior to initiating the study. The MRI studies will be reviewed by a neuroradiologist (Dr. Karimi) to rule out gross structural CNS abnormalities; in case any abnormalities considered to require clinical follow-up are detected, the subject will be contacted and referred for follow-up with their treating physician. Patients will undergo a brief neuropsychological test battery at MSKCC or at Citigroup Biomedical Imaging Center at WCMC
- OTHER
-
Neuroimaging & Neuropsychological Evaluation
Will undergo structural and functional MRI scans on a Siemens 3T Magnetom Tim Trio research scanner located at the Citigroup Biomedical Imaging Center at Weill Cornell Medical Center (WCMC), which is adjacent to the MSKCC campus. Patients do not undergo routine clinical brain MRIs as part of their assessment and treatment, and the brain MRI scans to be performed in this study are for research purposes only. The MRI scan takes approximately 60 minutes to complete, and about 15 minutes will be required for instructions prior to initiating the study. The MRI studies will be reviewed by a neuroradiologist (Dr. Karimi) to rule out gross structural CNS abnormalities; in case any abnormalities considered to require clinical follow-up are detected, the subject will be contacted and referred for follow-up with their treating physician. Patients will undergo a brief neuropsychological test battery at MSKCC or at Citigroup Biomedical Imaging Center at WCMC
Sponsors & Collaborators
-
Weill Medical College of Cornell University
collaborator OTHER -
Rutgers University
collaborator OTHER -
Memorial Sloan Kettering Cancer Center
lead OTHER
Principal Investigators
-
Denise Correa, PhD · Memorial Sloan Kettering Cancer Center
Eligibility
- Min Age
- 21 Years
- Max Age
- 70 Years
- Sex
- FEMALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2012-04-24
- Primary Completion
- 2022-05-25
- Completion
- 2022-05-25
Countries
- United States
Study Locations
More Related Trials
-
Homologous Recombination Inquiry Through Ovarian Malignancy Investigations
NCT03159572 ·Status: COMPLETED
-
Ovarian Cancer Radiomics Approach in CT Led Evaluation
NCT06817174 ·Status: RECRUITING
-
Use of New MolEcular MarkErs for a persoNalized Therapy in Ovarian Cancer-MEMENTO
NCT06917469 ·Status: COMPLETED
-
Effect of Serotonin Level on Constipation Caused by Chemotherapy in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT00536523 ·Status: TERMINATED
-
Retrospective Case Study to Validate Existing Chemoresponse Marker Test in Ovarian, Peritoneal or Fallopian Cancer Cases
NCT01048814 ·Status: COMPLETED
-
A New Fast DWI-based MR Protocol for Surveillance in Patients With a High Risk of Ovarian Cancer Recurrence During PARP-inhibitors Maintenance to Enhance Secondary Cytoreduction Results
NCT06541171 ·Status: NOT_YET_RECRUITING
-
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
NCT01422265 ·Status: COMPLETED
-
Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer
NCT01652794 ·Status: COMPLETED ·Phase: PHASE1
-
Prognostic Value of MRD Detection in CA125 Non-sensitive Ovarian Cancer Patients
NCT06182917 ·Status: RECRUITING
-
Unravelling Tumour Biology In Ovarian Cancer With Precision Imaging
NCT06084195 ·Status: RECRUITING ·Phase: NA
-
Quality-of-Life Study of Patients With Previously Treated Ovarian Cancer
NCT00003794 ·Status: TERMINATED
-
Sexual Therapy and Rehabilitation After Treatment for Ovarian Cancer (START-OC): A Pilot Intervention
NCT02287519 ·Status: COMPLETED ·Phase: NA
-
A Multicenter Trial On The Utility and Impact Of Computed Tomography and Serum CA-125 In the Management of Newly Diagnosed Ovarian Cancer
NCT00587093 ·Status: COMPLETED ·Phase: NA
-
Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients
NCT01579812 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Prognostic Monitoring for Women Who Have Completed Standard Treatment for Ovarian Cancer
NCT05410015 ·Status: RECRUITING
-
Sexual Functioning After Primary Treatment of Ovarian Cancer
NCT00596544 ·Status: TERMINATED
-
Intra-peritoneal Chemotherapy in Ovarian Cancer
NCT02861872 ·Status: UNKNOWN
-
O-RADS MRI System on Early Detection of Ovarian Cancer
NCT07009743 ·Status: ACTIVE_NOT_RECRUITING
-
Microvascular Ultrasonographic Imaging for the Detection of Early Stage Epithelial Ovarian Carcinoma
NCT00531570 ·Status: COMPLETED
-
ChemoFx® PRO - A Post-Market Data Collection Study
NCT00669422 ·Status: TERMINATED
-
Sentinel Node Detection in Clinical Early Stage Ovarian Cancer
NCT01734746 ·Status: COMPLETED ·Phase: NA
-
Pathway to Diagnosis of Ovarian Cancer
NCT01061619 ·Status: UNKNOWN
-
Clinical Trial to Screen Participants Who Are at High Genetic Risk for Ovarian Cancer
NCT00039559 ·Status: UNKNOWN ·Phase: NA
-
EC17 for Intraoperative Imaging in Occult Ovarian Cancer
NCT02000778 ·Status: COMPLETED ·Phase: PHASE1
-
Search for Predictors of Therapeutic Response in Ovarian Carcinoma
NCT01391351 ·Status: COMPLETED ·Phase: NA